About Us

Hebe Biotechnology is a privately-held Singaporean biotechnology company founded in 2024. We are a pre-clinical biotech company poised to advance our optimized candidate into pre-clinical proof of concept (PoC) studies. Our unique value proposition addresses a critical unmet need in obesity treatment, leveraging the potential of GLP-1 agonists. With a dedicated team with an extensive track record in discovering and developing GLP-1 receptor agonists (GLP-1 RAs), we are committed to being first or best in class.

Our assets are currently in the final stages of optimization, with plans for animal PoC by 2025. An early exit strategy is also under consideration for 2027, positioning us for significant growth in the near future.

Meet the Team